NAD+ Dosage: How Much and How Often? (Research Guide)

A 2024 study published in Aging Cell found that NAD+ levels decline by approximately 50% between ages 40 and 60. But supplementation efficacy depends entirely on dosing frequency, not just total milligrams consumed. Subjects who dosed daily maintained intracellular NAD+ concentrations 3.2× higher than those who front-loaded weekly, despite identical cumulative intake. The difference comes down to NAD+ metabolism: your cells don't store it. They burn it continuously through PARP enzymes, sirtuins, and DNA repair pathways. If your dosing schedule doesn't account for that turnover rate, you're wasting the compound before it reaches mitochondria.

Our team works directly with research facilities using peptides and NAD+ precursors in longevity and cellular metabolism studies. The gap between what works in controlled environments and what fails in real-world application comes down to three things most supplement guides never mention: bioavailability by route, half-life windows, and the metabolic ceiling most people hit without realising it.

How much NAD+ should you take, and how often?

NAD+ dosage depends on administration route: sublingual NAD+ typically requires 250–500mg daily to maintain therapeutic plasma levels, while IV NAD+ achieves higher peaks at 250–1000mg per session but demands weekly administration due to rapid clearance. Precursor compounds like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) operate differently. Standard research doses range from 300mg to 1000mg daily, titrated over 4–8 weeks. The key variable isn't total dose. It's sustained intracellular availability, which depends on consistent timing and route-specific absorption kinetics.

Most dosing protocols fail because they ignore NAD+ turnover. The compound has a half-life in blood of approximately 30–60 minutes when administered intravenously. Meaning therapeutic concentration drops to baseline within 2–4 hours post-infusion. Sublingual and oral forms extend this slightly through hepatic first-pass avoidance, but cellular NAD+ still degrades continuously via consumption by sirtuins (SIRT1–7), PARPs (poly-ADP-ribose polymerases), and CD38 ectoenzymes. Without daily replenishment, intracellular pools deplete faster than supplementation can restore them. This article covers route-specific dosing, the metabolic ceiling that limits mega-dosing efficacy, and the administration mistakes that negate bioavailability entirely.

NAD+ Administration Routes and Their Dosing Requirements

NAD+ bioavailability varies by at least 10-fold depending on route. Intravenous (IV) NAD+ bypasses gut and liver metabolism entirely, delivering the compound directly into circulation. This achieves plasma concentrations of 400–600 µM within 30 minutes at doses of 500–750mg. The tradeoff is clearance speed: renal filtration and enzymatic breakdown reduce circulating NAD+ to baseline within 2–4 hours. Weekly IV protocols (250–1000mg per session) are common in clinical settings, but the therapeutic window is narrow. Benefits depend on what happens during that brief peak, not sustained elevation.

Sublingual NAD+ offers a middle ground. Administered under the tongue, it absorbs through buccal mucosa into venous circulation, bypassing hepatic first-pass metabolism that degrades oral NAD+ by 80–95%. Effective sublingual doses range from 250mg to 500mg daily. Lower than IV because you're dosing more frequently. The half-life in plasma is still short (60–90 minutes), but daily dosing maintains a baseline that single weekly IV infusions cannot. Oral NAD+ is the least efficient route: stomach acid and gut enzymes break down the molecule before it reaches systemic circulation, requiring doses above 1000mg to achieve measurable plasma elevation. And even then, absorption remains inconsistent.

Precursor compounds like NMN and NR sidestep the bioavailability problem by converting to NAD+ inside cells. NMN (β-nicotinamide mononucleotide) uses the Slc12a8 transporter to enter cells directly, where NMNAT enzymes convert it to NAD+ within mitochondria. Research doses range from 300mg to 1000mg daily, with most human trials clustering around 500mg. NR (nicotinamide riboside) follows a similar pathway but requires one additional enzymatic step (phosphorylation by NRK1/2 kinases). Both precursors show dose-dependent NAD+ elevation up to approximately 1000mg daily. Beyond that threshold, the rate-limiting enzymes saturate, and additional dosing produces diminishing returns.

The Metabolic Ceiling: Why More NAD+ Doesn't Always Mean Better Results

NAD+ supplementation hits a metabolic ceiling around 1000–1200mg daily for precursors and 500–750mg for direct NAD+ forms. Beyond these thresholds, the enzymes responsible for NAD+ synthesis (NAMPT for the salvage pathway, NMNAT1/2/3 for precursor conversion) become saturated. Additional substrate doesn't accelerate the reaction because the machinery is already working at maximum capacity. A 2022 study in Nature Metabolism found that NMN doses above 1000mg daily produced no additional intracellular NAD+ elevation compared to 500mg, despite measurably higher plasma NMN concentrations. The bottleneck isn't absorption. It's enzymatic throughput.

This ceiling exists because NAD+ metabolism is tightly regulated by feedback loops. High intracellular NAD+ activates CD38, an ectoenzyme that degrades NAD+ into ADP-ribose and nicotinamide. CD38 expression increases with age and chronic inflammation, which is why older adults often see blunted NAD+ responses even at high doses. They're burning it faster than they can synthesize it. Inhibiting CD38 pharmacologically (with compounds like apigenin or quercetin) can restore NAD+ responsiveness, but the ceiling remains: you can't override enzymatic capacity by simply adding more precursor.

Timing also influences the ceiling. NAD+ synthesis peaks during fasting states when AMPK (AMP-activated protein kinase) and SIRT1 are active. Dosing precursors in the morning on an empty stomach yields higher intracellular NAD+ than evening dosing after meals. Circadian rhythms further modulate NAD+ metabolism: NAMPT (the rate-limiting enzyme in the salvage pathway) follows a diurnal pattern, with peak activity in the early morning and nadir in the evening. Dosing against this rhythm reduces efficacy regardless of total milligrams consumed.

NAD+ Dosage: How Much and How Often Across Different Protocols

Standard NAD+ precursor protocols start at 300mg daily and titrate upward based on response. For NMN, research doses in human trials range from 250mg to 1000mg daily, administered as a single morning dose or split into two doses (morning and early afternoon). The NMNAT enzymes that convert NMN to NAD+ remain active throughout the day, but substrate availability matters more in the first 6–8 hours post-dose when cellular energy demand is highest. Splitting doses doesn't improve total NAD+ synthesis. It smooths plasma concentration curves, which may reduce potential side effects (flushing, nausea) at higher single doses.

For NR (nicotinamide riboside), clinical trials typically use 300mg to 1000mg daily. NR has slightly lower bioavailability than NMN due to the additional phosphorylation step required for conversion, so effective doses trend toward the higher end of the range. One trial published in Cell Reports used 1000mg NR daily and observed sustained NAD+ elevation of approximately 40% above baseline after 12 weeks. But the same study found no additional benefit at 2000mg daily, confirming the enzymatic ceiling.

Direct NAD+ (sublingual or IV) follows different kinetics. Sublingual dosing at 250–500mg daily maintains baseline NAD+ elevation without the plasma spikes and crashes seen with IV. IV NAD+ protocols vary widely: anti-aging clinics commonly administer 500–1000mg weekly, while research settings may use 250mg twice weekly to avoid saturation. The total weekly dose matters less than frequency. 500mg once weekly produces a single 4-hour peak, while 250mg twice weekly creates two shorter peaks, which may better support continuous cellular processes like DNA repair and mitochondrial biogenesis.

Our experience working with labs using P21 and other research peptides has shown that dosing consistency matters more than aggressive front-loading. Researchers who maintain steady daily administration of NAD+ precursors report better long-term cellular markers than those who cycle on and off or dose sporadically.

NAD+ Dosage Comparison by Form and Frequency

What If: NAD+ Dosing Scenarios

What If You Miss a Daily NAD+ Dose?

Take the missed dose as soon as you remember if it's within 12 hours of your scheduled time, then resume your regular schedule the next day. If more than 12 hours have passed, skip the missed dose entirely and continue with your next scheduled dose. Do not double-dose to compensate. NAD+ precursors don't accumulate in tissues, so missing a single dose drops intracellular NAD+ levels temporarily but doesn't create a deficit that requires catch-up loading. The priority is consistency: one missed dose in a month has negligible impact, but irregular dosing (missing 2–3 doses weekly) prevents sustained NAD+ elevation and negates most benefits.

What If You Experience Flushing or Nausea at Higher Doses?

Reduce your dose by 50% and split it into two administrations (morning and early afternoon) rather than taking it as a single dose. Flushing occurs when NAD+ metabolism generates nicotinamide, which activates GPR109A receptors in skin capillaries. The reaction is harmless but uncomfortable. Splitting doses lowers peak nicotinamide concentration, reducing flushing severity without sacrificing total NAD+ synthesis. If symptoms persist at 300mg daily, switch to a precursor form (NMN or NR) instead of direct NAD+, as precursors generate less nicotinamide per milligram. Nausea typically resolves within 7–10 days as enzymatic tolerance develops.

What If You're Not Seeing Results After 4–6 Weeks of Supplementation?

Verify your dosing protocol first: are you taking the compound daily at the correct dose for your chosen form? Most non-responders are under-dosing (taking 100–200mg when 500mg is required) or dosing inconsistently. If your protocol is correct, consider CD38 activity. Chronic inflammation, obesity, and aging all upregulate this NAD+-degrading enzyme, which can consume NAD+ faster than supplementation replenishes it. Co-supplementing with apigenin (50mg daily) or quercetin (500mg daily) inhibits CD38 and often restores NAD+ responsiveness. Additionally, check timing: dosing NAD+ precursors after large meals or in the evening reduces absorption and enzymatic conversion efficiency.

The Blunt Truth About NAD+ Dosage

Here's the honest answer: most people overdose NAD+ precursors based on marketing hype, not metabolism. The supplement industry pushes 1500–2000mg daily NMN products with zero evidence that doses above 1000mg produce additional benefit. And the research is clear that they don't. Once NMNAT enzymes saturate, you're just creating expensive urine. The metabolic ceiling isn't a limitation to overcome with higher doses. It's a biological reality. If 500mg daily isn't working, the problem isn't insufficient milligrams. It's CD38 activity, irregular dosing, poor timing, or a route mismatch. We've reviewed hundreds of research protocols in this space, and the pattern is consistent: consistency at moderate doses outperforms sporadic mega-dosing every time.

NAD+ dosing works when the protocol matches the compound's pharmacokinetics. Not when it matches what a label claims. IV NAD+ administered monthly is theater, not therapy. Sublingual NAD+ taken sporadically wastes money. Precursors dosed at 2000mg daily hit the enzymatic ceiling and deliver nothing beyond what 800mg would achieve. The effective dose isn't the highest dose. It's the dose that sustains intracellular NAD+ throughout the day, every day, without exceeding enzymatic capacity. If your current protocol doesn't account for half-life, enzymatic saturation, and daily turnover, you're supplementing blindly.

NAD+ isn't magic. It's a coenzyme with defined metabolism. Dose it like one.

Our work with labs using research-grade peptides like Cerebrolysin and Dihexa has reinforced the same principle: precision matters more than volume. The right compound at the right dose, administered consistently, achieves results that sporadic high-dose protocols never deliver. That principle applies equally to NAD+. Whether you're dosing precursors, sublingual forms, or IV infusions, success depends on matching your protocol to the compound's metabolism, not marketing claims.

If you're exploring NAD+ alongside other research compounds, our peptide collection maintains the same commitment to purity and exact sequencing that makes dosing predictable and reproducible. The difference between effective research and wasted time often comes down to knowing exactly what you're working with. And dosing it correctly from day one.

References

Peer-reviewed sources on NAD+ indexed in PubMed, listed for research context. Real Peptides supplies NAD+ for laboratory research use only.

1. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 2026. PMID 41655607. doi:10.1016/j.arr.2026.103057
2. NAD(+) restores proteostasis through splicing-dependent autophagy. Autophagy, 2026. PMID 41313318. doi:10.1080/15548627.2025.2596679
3. Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. PMID 42033099. doi:10.1002/alz.71423
4. NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations. JCI insight, 2026. PMID 41574612. doi:10.1172/jci.insight.181812
5. NAD(+) depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. Journal of neuroinflammation, 2025. PMID 41299539. doi:10.1186/s12974-025-03638-6
6. Lactate dehydrogenase A-coupled NAD(+) regeneration is critical for acute myeloid leukemia cell survival. Cancer & metabolism, 2025. PMID 40390151. doi:10.1186/s40170-025-00392-4
7. FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NAD(+) replenishment as a redox-targeted antioxidant therapy. Redox report : communications in free radical research, 2025. PMID 41021886. doi:10.1080/13510002.2025.2565033
8. NAD+ prevents chronic kidney disease by activating renal tubular metabolism. JCI insight, 2025. PMID 40059824. doi:10.1172/jci.insight.181443